CRISPR Therapeutics AG (CRSP)

CRISPR Therapeutics AG
TickerCRSP
ISINUS0334081132
CIK0001674416
BoerseUS
55,08
Schluss · 06.05.2026
1T+5,2 %1W+8,6 %1M+12,1 %3M+9,8 %6M−3,4 %1J+66,1 %

Sentiment-Signal

30,3
Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
65.4
4 neu, 13 erhöht, -3526639K $ netto
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)

Score-Verlauf (90 Tage)

Stammdaten

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

Unternehmen & Branche

NameCRISPR Therapeutics AG
TickerCRSP
CIK0001674416
BoerseUS
SektorHealthcare
IndustrieBiotechnology
SIC2836 · Biological Products, (No Diagnostic Substances)

Wertpapier & Kennzahlen

CUSIP033408113
ISINUS0334081132
TypCommon Stock
Marktkapitalisierung5,06 Mrd. USD
Beta1,74
Dividendenrendite0,00 %

Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »

Finanzkennzahlen (SEC XBRL)

PeriodeFilingUmsatzNettoergebnisEPSAktivaEigenkapital
2025-12-3110-K3,510,000-581,599,000-6.472,265,243,0001,921,813,000
2025-09-3010-Q889,000-106,441,000-1.172,245,308,0001,915,982,000
2025-06-3010-Q892,000-208,549,000-2.402,029,711,0001,711,125,000
2025-03-3110-Q865,000-135,996,000-1.582,166,102,0001,829,160,000
2024-12-3110-K37,314,000-366,252,000-4.342,242,034,0001,932,080,000
2024-09-3010-Q602,000-85,942,000-1.012,256,130,0001,939,658,000
2024-06-3010-Q517,000-126,408,000-1.492,339,853,0001,980,949,000
2024-03-3110-Q504,000-116,591,000-1.432,439,017,0002,083,936,000
2023-12-3110-K371,206,000-153,610,000-1.942,229,571,0001,882,803,000
2023-09-3010-Q0-112,152,000-1.412,086,830,0001,727,794,000
2023-06-3010-Q70,000,000-77,740,000-0.982,197,014,0001,816,028,000
2023-03-3110-Q100,000,000-53,065,000-0.672,244,364,0001,854,896,000
2022-12-3110-K1,198,000-650,175,000-8.362,243,057,0001,875,479,000
2022-09-3010-Q94,000-174,549,000-2.242,353,356,0001,953,954,000
2022-06-3010-Q158,000-185,834,000-2.402,463,363,0002,090,831,000
2022-03-3110-Q940,000-179,217,000-2.322,606,175,0002,244,916,000
2021-12-3110-K914,963,000377,661,0004.702,751,877,0002,399,460,000
2021-09-3010-Q824,000-127,153,000-1.672,821,725,0002,512,923,000
2021-06-3010-Q900,701,000759,225,0009.442,899,519,0002,603,795,000
2021-03-3110-Q539,000-113,163,000-1.511,957,910,0001,805,498,000

Fondsaktivität (Vorquartalsvergleich)

FondsAktuell (Stk)Vorquartal (Stk)Veränderung (Stk)Wert (USD)StatusΔTrend
ARK Investment Management LLC10,522,057010,522,057551,776,677Neu+100,0%
BlackRock, Inc.7,508,17807,508,178393,728,856Neu+100,0%
Orbis Allan Gray Ltd5,950,14505,950,145312,025,603Neu+100,0%
Capital International Investors5,892,74505,892,745309,015,548Neu+100,0%
STATE STREET CORP3,753,44003,753,440196,830,394Neu+100,0%
VANGUARD GROUP INC2,268,39402,268,394118,954,581Neu+100,0%
GEODE CAPITAL MANAGEMENT, LLC2,249,22302,249,223117,970,852Neu+100,0%
SUSQUEHANNA INTERNATIONAL GROUP, LLP2,098,27102,098,271110,033,331Neu+100,0%
SR ONE CAPITAL MANAGEMENT, LP2,038,76302,038,763106,912,732Neu+100,0%
FMR LLC1,953,95701,953,957102,465,517Neu+100,0%
CITADEL ADVISORS LLC1,604,58501,604,58584,144,437Neu+100,0%
UBS Group AG1,762,5302,524,144-761,61483,843,552Reduziert-30,2%
BANK OF AMERICA CORP /DE/1,096,88701,096,88757,520,761Neu+100,0%
CHARLES SCHWAB INVESTMENT MANAGEMENT INC1,030,18201,030,18254,022,744Neu+100,0%
JANE STREET GROUP, LLC904,6000904,60047,437,224Neu+100,0%
LOOMIS SAYLES & CO L P899,3310899,33147,160,918Neu+100,0%
NORTHERN TRUST CORP755,1050755,10539,597,706Neu+100,0%
Squarepoint Ops LLC702,9080702,90836,860,496Neu+100,0%
IMC-Chicago, LLC677,9000677,90035,549,076Neu+100,0%
MORGAN STANLEY667,0600667,06034,980,655Neu+100,0%
JPMORGAN CHASE & CO596,1540596,15431,262,316Neu+100,0%
GROUP ONE TRADING LLC581,9540581,95430,517,668Neu+100,0%
Caption Management, LLC550,6000550,60028,873,464Neu+100,0%
NATIONAL BANK OF CANADA /FI/58,427058,42728,512,907Neu+100,0%
NORGES BANK490,2060490,20625,706,403Neu+100,0%
TWO SIGMA INVESTMENTS, LP470,6210470,62124,679,365Neu+100,0%
DIMENSIONAL FUND ADVISORS LP494,218907,107-412,88923,487,779Reduziert-45,5%
D. E. Shaw & Co., Inc.411,3000411,30021,568,572Neu+100,0%
PEAK6 LLC370,9740370,97419,453,877Neu+100,0%
BARCLAYS PLC344,9880344,98818,091,170Neu+100,0%
SIMPLEX TRADING, LLC322,5000322,50016,911,900Neu+100,0%
WELLS FARGO & COMPANY/MN318,9780318,97816,727,226Neu+100,0%
AMERIPRISE FINANCIAL INC297,2440297,24415,568,334Neu+100,0%
GOLDMAN SACHS GROUP INC275,6320275,63214,454,142Neu+100,0%
Nuveen, LLC190,766183,3847,3829,074,739Aufgestockt+4,0%
LPL Financial LLC170,8310170,8318,958,351Neu+100,0%
RAYMOND JAMES FINANCIAL INC167,1480167,1488,765,240Neu+100,0%
ROYAL BANK OF CANADA165,5650165,5658,682,000Neu+100,0%
Swiss National Bank169,700161,5008,2008,072,629Aufgestockt+5,1%
Walleye Trading LLC149,5100149,5107,840,304Neu+100,0%
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC148,9010148,9017,808,370Neu+100,0%
Versant Venture Management, LLC148,8310148,8317,804,698Neu+100,0%
CITIGROUP INC132,6930132,6936,958,421Neu+100,0%
Pictet Asset Management Holding SA154,007167,464-13,4576,874,475Reduziert-8,0%
Marex Group plc127,5460127,5466,688,512Neu+100,0%
No Street GP LP125,0000125,0006,555,000Neu+100,0%
RHUMBLINE ADVISERS118,7780118,7786,228,704Neu+100,0%
CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM116,1040116,1046,088,494Neu+100,0%
Rockefeller Capital Management L.P.112,6670112,6675,908,258Neu+100,0%
TUDOR INVESTMENT CORP ET AL108,4680108,4685,688,062Neu+100,0%

Insider-Transaktionen (12 Monate)

DatumInsiderRolleTypStückzahlKursWert (USD)ΔTrend
2026-03-16Kulkarni SamarthDirector, Officer, Chief Executive OfficerOpen Market Sale-10,34948.26-499,442.74-10,2%
2026-03-11Kulkarni SamarthDirector, Officer, Chief Executive OfficerOpen Market Sale-9,79852.80-517,334.40-10,6%
2026-02-19Kulkarni SamarthDirector, Officer, Chief Executive OfficerOpen Market Sale-6,96752.58-366,324.86-7,5%
2026-01-22Kulkarni SamarthDirector, Officer, Chief Executive OfficerOpen Market Sale-60,00060.23-3,613,800.00-73,8%
2026-01-20Kulkarni SamarthDirector, Officer, Chief Executive OfficerOpen Market Sale-8,56752.10-446,340.70-9,1%
2026-01-20Kulkarni SamarthDirector, Officer, Chief Executive OfficerOpen Market Sale-21,43351.61-1,106,157.13-22,6%
2025-10-17Kulkarni SamarthDirector, Officer, Chief Executive OfficerOpen Market Sale-50,89567.91-3,456,279.45-70,5%
2025-10-14Kulkarni SamarthDirector, Officer, Chief Executive OfficerOpen Market Sale-4,24266.60-282,517.20-5,8%
2025-08-18Kulkarni SamarthDirector, Officer, Chief Executive OfficerOpen Market Sale-13,08158.15-760,660.15-15,5%
2025-08-06Treco Douglas ADirectorOpen Market Purchase20,00057.031,140,600.00+23,3%
2025-07-16George SimeonDirectorOpen Market Purchase6,51052.03338,715.30+6,9%
2025-07-16George SimeonDirectorOpen Market Purchase960,98352.0349,999,945.49+1020,6%
2025-07-16George SimeonDirectorOpen Market Purchase22,31952.031,161,257.57+23,7%

Top-Fondshalter

Stand: 31.03.2026

FondsAnteileWert (USD)Anteil (%)
UBS Group AG1,762,53083,843,55243.74
DIMENSIONAL FUND ADVISORS LP494,21823,487,77912.25
Nuveen, LLC190,7669,074,7394.73
Swiss National Bank169,7008,072,6294.21
Pictet Asset Management Holding SA154,0076,874,4753.59
CONGRESS ASSET MANAGEMENT CO108,3715,155,2082.69
Baker Chad R93,3004,438,2812.32
Slow Capital, Inc.91,2234,339,4792.26
Legal & General Group Plc75,6403,598,1951.88
Green Alpha Advisors, LLC57,0222,712,5371.42
Patriot Financial Group Insurance Agency, LLC47,5502,261,9541.18
Russell Investments Group, Ltd.47,4482,257,1621.18
Privium Fund Management B.V.42,8742,039,5161.06
Wealth Enhancement Trust Services, Inc.38,8531,848,2370.96
West Family Investments, Inc.35,5001,688,7350.88
BRAVE ASSET MANAGEMENT INC34,7341,652,2960.86
Bouvel Investment Partners, LLC32,5191,546,9290.81
State of New Jersey Common Pension Fund D29,3131,394,4190.73
WEALTH ENHANCEMENT ADVISORY SERVICES, LLC26,6771,320,7780.69
HSBC HOLDINGS PLC25,8871,213,0650.63

Hinweis

Erweitert ×